# US 2017/0283486 A1 · Stable immunogen based on inner domain of hiv-1 gp120 for inducing immunity against hiv

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283486 A1
- Document ID: US20170283486A1
- Status: Published application
- Kind: A1
- Application number: 15/504,770
- Filed: 2015-08-19
- Published: 2017-10-05
- Earliest claimed: 2014-08-20
- Assignees: University of Maryland, Baltimore
- Inventors: Marzena PAZGIER; George LEWIS; William TOLBERT; Neelakshi GOHAIN
- Web page: https://patentgrep.com/patent/US20170283486A1

## CPC

- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/385: Haptens or antigens, bound to carriers
- C07K 14/005: from viruses
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/575: {humoral response}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Stable immunogens comprising portions of the inner domain (ID) of the Human Immunodeficiency Virus (HIV-1) gp120 protein are provided. These ID immunogens selectively present the gp120 C1/C2 region in its CD4-bound state within a minimal structure. These ID immunogens can be used to vaccinate subjects against infection with HIV, the causative agent of Acquired Immunodeficiency Syndrome (AIDS). The immunogens can also be used as targets in screening to identify small molecule or peptide inhibitors that block HIV-1 viral entry and attachment steps, and as probes for identifying gp120 C1/C2 region-specific antibodies.

## Claims

### Claim 1

A HIV-1 gp120 inner domain (ID) immunogen, where the ID immunogen comprises:
(a) a mature human immunodeficiency virus 1 (HIV-1) gp120 polypeptide having two or more of the features (i)-(iv):
(i) deletion of amino acids 1-11 of the N-terminus,
(ii) cysteine residues at amino acids positions 65 and 115,
(iii) deletion of amino acids 258-472 of the outer domain region and replacement by a GlyGly dipeptide linker, and
(iv) deletion of amino acids 119-205 of the V1V2 loop and replacement by a GlyGlyAla tripeptide linker,
wherein the amino acid numbering corresponds to the amino acid sequence set forth in SEQ ID NO:1; or
(b) a variant having at least about 95% sequence identity with an immunogen of (a) over the entire length of the immunogen sequence.

### Claim 2 (depends on 1)

The ID immunogen of claim 1, wherein the ID immunogen of (a) has three or more of the features (i)-(iv).

### Claim 3 (depends on 1)

The ID immunogen of claim 1, wherein the ID immunogen of (a) has features (i)-(iii).

### Claim 4 (depends on 1)

The ID immunogen of claim 1, wherein the ID immunogen of (a) has features (i)-(iv).

### Claim 5

A HIV-1 gp120 ID immunogen comprising an amino acid sequence set forth in any one of SEQ ID NOs:3-54 or a variant thereof having at least about 95% sequence identity with the immunogen over the entire length of the immunogen sequence.

### Claim 6 (depends on 1)

The ID immunogen of claim 1, wherein the variant has the property of inducing a humoral Fc-mediated effector response to C1/C2 or combined C1/C2 and V1/V2 regions of HIV-1 gp120.

### Claim 7 (depends on 1)

The ID immunogen of claim 1, wherein the immunogen has a C65-C115 disulfide bond.

### Claim 8 (depends on 1)

An immunogenic composition comprising one or more ID immunogens and a pharmaceutically-acceptable carrier or diluent, wherein the ID immunogens are selected from those set forth in claim 1.

### Claim 9 (depends on 8)

The immunogenic composition of claim 8, wherein the composition comprises one specific ID immunogen.

### Claim 10 (depends on 8)

The immunogenic composition of claim 8, wherein the composition comprises two or more different ID immunogens.

### Claim 11 (depends on 8)

The immunogenic composition of claim 8, wherein the composition comprises one or more ID immunogens set forth in SEQ ID NOs:3-54.

### Claim 12 (depends on 8)

A method of inducing an immune response to an ID immunogen in a subject, comprising administering to a subject an immunogenic amount of an immunogenic composition of claim 8, thereby inducing an immune response in the subject.

### Claim 13 (depends on 11)

A method of inducing an immune response to an ID immunogen in a subject, comprising administering to a subject an immunogenic amount of an immunogenic composition of claim 11, thereby inducing an immune response in the subject.

### Claim at position 14

14-23. (canceled)

### Claim 24 (depends on 5)

The ID immunogen of claim 5, wherein the variant has the property of inducing a humoral Fc-mediated effector response to C1/C2 or combined C1/C2 and V1/V2 regions of HIV-1 gp120.

### Claim 25 (depends on 5)

The ID immunogen of claim 5, wherein the immunogen has a C65-C115 disulfide bond.

### Claim 26 (depends on 5)

The ID immunogen of claim 5, wherein the ID immunogen is ID2 set forth in SEQ ID NO:57.

### Claim 27 (depends on 7)

The ID immunogen of claim 7, wherein the ID immunogen is ID2 set forth in SEQ ID NO:57.

### Claim 28 (depends on 5)

An immunogenic composition comprising one or more ID immunogens and a pharmaceutically-acceptable carrier or diluent, wherein the ID immunogens are selected from those set forth in claim 5.

### Claim 29 (depends on 28)

The immunogenic composition of claim 28, wherein the composition comprises one or more ID immunogens set forth in SEQ ID NOs:3-54.

### Claim 30 (depends on 29)

A method of inducing an immune response to an ID immunogen in a subject, comprising administering to a subject an immunogenic amount of an immunogenic composition of claim 29, thereby inducing an immune response in the subject.
